Vigil Neuroscience (VIGL) News Today → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free VIGL Stock Alerts $2.77 +0.12 (+4.53%) (As of 04/24/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVigil Neuroscience (NASDAQ:VIGL) Rating Reiterated by JMP Securitiesamericanbankingnews.com - April 20 at 1:54 AMJMP Securities Reaffirms Market Outperform Rating for Vigil Neuroscience (NASDAQ:VIGL)marketbeat.com - April 18 at 2:21 PMVigil Neuroscience Inc: A Strong Buy on Promising ALSP Drug Trial Outcomes and Biomarker Breakthroughsmarkets.businessinsider.com - April 18 at 9:06 AMVigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meetingglobenewswire.com - April 17 at 4:05 PMVigil Neuroscience, Inc. Forecasted to Post Q2 2024 Earnings of ($0.58) Per Share (NASDAQ:VIGL)marketbeat.com - March 29 at 8:16 AMBuy Rating Affirmed for Vigil Neuroscience on Promising Clinical Trials and Key Data Readoutsmarkets.businessinsider.com - March 29 at 8:12 AMBrokers Issue Forecasts for Vigil Neuroscience, Inc.'s Q1 2024 Earnings (NASDAQ:VIGL)marketbeat.com - March 28 at 8:18 AMAnalysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL) and Daxor (DXR)markets.businessinsider.com - March 27 at 12:58 PMVigil Neuroscience (NASDAQ:VIGL) Stock Rating Reaffirmed by HC Wainwrightmarketbeat.com - March 27 at 10:15 AMBuy Rating Affirmed: Vigil Neuroscience’s Advancing TREM2 Programs and Strong Financial Positionmarkets.businessinsider.com - March 27 at 7:41 AMVigil Neuroscience, Inc. (NASDAQ:VIGL) Forecasted to Earn FY2028 Earnings of ($0.58) Per Sharemarketbeat.com - March 27 at 6:34 AMVigil Neuroscience, Inc.: Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updatefinanznachrichten.de - March 26 at 11:28 PMVigil Neuroscience GAAP EPS of -$0.57 in-linemsn.com - March 26 at 11:27 PMVigil Neuroscience: Q4 Earnings Insightsbenzinga.com - March 26 at 11:27 PMVIGL Stock Earnings: Vigil Neuroscience Misses EPS for Q4 2023investorplace.com - March 26 at 3:01 PMVigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updateglobenewswire.com - March 26 at 7:05 AMIs Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - March 24 at 9:59 AMVigil Neuroscience, Inc.: Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officerfinanznachrichten.de - March 20 at 5:39 PMVigil Neuroscience appoints Kaufmann as Chief Medical Officerseekingalpha.com - March 20 at 5:39 PMVigil Neuroscience Appoints Petra Kaufmann As CMOmarkets.businessinsider.com - March 20 at 5:39 PMVigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officerglobenewswire.com - March 20 at 7:05 AMVIGL Vigil Neuroscience, Inc.seekingalpha.com - March 16 at 12:03 AMVigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meetingglobenewswire.com - March 13 at 7:05 AMVigil Neuroscience to Present at Stifel 2024 Virtual CNS Daysglobenewswire.com - March 12 at 7:05 AMVigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024globenewswire.com - March 6 at 4:25 PMVigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024globenewswire.com - February 29 at 4:05 PMVigil Neuroscience Stock (NASDAQ:VIGL) Insider Tradesbenzinga.com - February 22 at 7:28 AMShort Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 9.3%marketbeat.com - February 15 at 7:22 AMVigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conferencefinance.yahoo.com - February 7 at 4:39 PMVigil Neuroscience (NASDAQ:VIGL) Stock Price Up 6.9%marketbeat.com - February 7 at 5:47 AMVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Updatemarketbeat.com - January 14 at 9:35 AMAnalysts Offer Insights on Healthcare Companies: AN2 Therapeutics, Inc. (ANTX) and Vigil Neuroscience Inc (VIGL)markets.businessinsider.com - January 5 at 8:00 PMVigil Neuroscience, Inc.: Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestonesfinanznachrichten.de - January 4 at 8:36 AMVigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestonesfinance.yahoo.com - January 3 at 7:59 PMMorgan Stanley Downgrades Vigil Neuroscience (VIGL)msn.com - December 20 at 3:50 PMVigil Neuroscience (NASDAQ:VIGL) Lowered to "Underweight" at Morgan Stanleymarketbeat.com - December 19 at 8:09 AMVigil Neuroscience Inc VIGLmorningstar.com - December 7 at 12:13 AMPromising Clinical Trial Results and Safety Profile Bolster Buy Rating for Vigil Neuroscience Inc: An In-depth Analysismarkets.businessinsider.com - November 22 at 11:06 PMVigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conferencefinance.yahoo.com - November 22 at 6:06 PMVigil Neuroscience: Interim Data Sheds Light On Possible Accelerated Pathwayseekingalpha.com - November 20 at 11:12 PMPromising IGNITE Trial Results Bolster Buy Rating for Vigil Neuroscience Inc: An Analysis of VGL101’s Potential in ALSP Treatmentmarkets.businessinsider.com - November 17 at 3:30 PMWhy Is Rare Neurological Disease Focused Vigil Neuroscience Stock Trading Lower Today?msn.com - November 17 at 3:30 PMVigil Neuroscience reports interim Phase 2 data for ALSP drug candidatemsn.com - November 16 at 10:59 PMVigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATEfinance.yahoo.com - November 16 at 5:58 PMVigil Neuroscience Inc: Potential for Accelerated Approval and Proof of Concept for VGL-101 Bolsters Buy Ratingmarkets.businessinsider.com - November 9 at 12:16 AMVigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 7 at 7:27 AMVigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 7 at 7:27 AMJMP Securities Initiates Coverage of Vigil Neuroscience (VIGL) with Market Outperform Recommendationmsn.com - October 18 at 11:19 PMVigil Neuroscience's Focus On Neurodegenerative Diseases: Analyst Says Pipeline Offers Upside Opportunities To Valuationmarkets.businessinsider.com - October 18 at 6:19 PMBuy Rating for Vigil Neuroscience Inc Due to Promising Neurodegenerative Disease Programs and Potential Billion-Dollar Market Opportunitymarkets.businessinsider.com - October 18 at 1:05 AM Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… VIGL Media Mentions By Week VIGL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIGL News Sentiment▼0.680.44▲Average Medical News Sentiment VIGL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIGL Articles This Week▼41▲VIGL Articles Average Week Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OTLK News Today LIFE News Today BLUE News Today CRDL News Today BCAB News Today SGMO News Today ZURA News Today AGEN News Today OMGA News Today CRIS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIGL) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry Research1970’s computer coder issues shocking A.I. warningTradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
